Migraine is a recurrent neurological disorder recognized by the World Health Organization as the second leading cause of disability. Currently, most available pharmacological interventions for migraine prevention and treatment are either non-specific or associated with contraindications and serious adverse reactions. Recent research has focused on calcitonin gene-related peptide (CGRP), which plays a pivotal role in the pathophysiological mechanisms underlying migraine. Targeted CGRP pathway inhibitors have been developed, including CGRP receptor antagonists (gepants) and anti-CGRP monoclonal antibodies. Current studies indicate that these agents demonstrate favorable safety profiles, efficacy,and tolerability. This paper reviewed relevant clinical trials and research findings of targeting the CGRP pathway, aiming to provide a foundation for future selection of domestic migraine therapeutics.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |